FEXOFENADINE

/static/temp/default.svg

Search structure


Synonyms	Allegra Fexofenadine
Status
Molecule Category	Free-form
ATC	R06AX26
UNII	E6582LOH6V
EPA CompTox	DTXSID00861411


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	RWTNPBWLLIMQHL-UHFFFAOYSA-N
Smiles	CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
InChI	InChI=1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C32H39NO4
Molecular Weight	501.67
AlogP	5.51
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	10.0
Polar Surface Area	81.0
Molecular species	ZWITTERION
Aromatic Rings	3.0
Heavy Atoms	37.0

Assay Description	Organism	Bioactivity	Reference
Inhibition of histamine H1 receptor	None	78.0 nM
Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting	Homo sapiens	78.0 nM
In vivo antihistaminic activity at histamine H1 receptor in ddY mouse assessed as inhibition of histamine-induced skin vascular permeability at 3 mg/kg, po administered 1 hr before histamine challenge measured after 30 mins by Evan's blue staining	Mus musculus	70.0 %
Antiinflammatory activity in BALB/c mouse model assessed as inhibition of ovalbumin-induced ear swelling at 10 mg/kg, po administered 60 mins before ovalbumin challenge measured 1 hr after elicitation by immediate type reaction assay	Mus musculus	61.0 %
Antiinflammatory activity in BALB/c mouse model assessed as inhibition of ovalbumin-induced ear swelling at 10 mg/kg, po administered 60 mins before ovalbumin challenge measured 24 hrs after elicitation by late type reaction assay	Mus musculus	6.0 %
Inhibition of human ERG in L929 cells by whole cell patch-clamp assay	Homo sapiens	100.0 nM
Inhibition of human ERG in L929 cells at 10 uM by whole cell patch-clamp assay	Homo sapiens	3.0 %
Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting	Homo sapiens	27.0 nM
Inhibition of CETP in rabbit serum at 10 uM after 1 hr by fluorescent cholesteryl esters transfer assay	Oryctolagus cuniculus	0.0 %
Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting	Homo sapiens	78.0 nM
Antiinflammatory activity in ovalbumin-sensitized BALB/c mouse biphasic allergic model assessed as immediate type reaction at 10 mg/kg, po administered 1 hr before ovalbumin challenge measured 1 hr after elicitation by ear swelling assay	Mus musculus	61.0 %
Antiinflammatory activity in ovalbumin-sensitized BALB/c mouse biphasic allergic model assessed as late type reaction at 10 mg/kg, po administered 1 hr before ovalbumin challenge measured 24 hrs after elicitation by ear swelling assay	Mus musculus	6.0 %
Antipruritic activity in ICR mouse assessed as inhibition of compound 48/80-induced scratching at 30 mg/kg, po measured after 30 mins	Mus musculus	39.0 %
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting	Homo sapiens	28.9 %
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting	Homo sapiens	6.0 %
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting	Homo sapiens	-5.8 %
Inhibition of histamine H1 receptor (unknown origin)	Homo sapiens	15.0 nM

Related Entries

Environmental Exposure

Environmental Exposure Map

Countries
USA

Cross References

Resources	Reference
ChEBI	5050
ChEMBL	CHEMBL914
DrugBank	DB00950
DrugCentral	1170
FDA SRS	E6582LOH6V
Human Metabolome Database	HMDB0005030
Guide to Pharmacology	4819
KEGG	C06999
PharmGKB	PA449621
PubChem	3348
SureChEMBL	SCHEMBL4900

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).